Literature DB >> 22941528

New imidazolidine derivatives as anti-Trypanosoma cruzi agents: structure-activity relationships.

Fabiana Oliveira Dos Santos Gomes1, Cristiane Moutinho Lagos de Melo, Christina Alves Peixoto, Maria do Carmo Alves de Lima, Suely Lins Galdino, Valéria Rêgo Alves Pereira, Ivan da Rocha Pitta.   

Abstract

Imidazolidine derivatives are key components for the development of bioactive compounds for the treatment of many diseases, especially Chagas. In fact, others studies showed that the imidazolidine-2,4-dione has stood out by presenting a wide spectrum of pharmacological activities including anticonvulsants, antiarrhythmic, and antiparasitic. In the present study, we investigated the morphological alterations induced by imidazolidine derivates LPSF/NN-52 and LPSF/NN-100 on trypomastigotes forms of Trypanosoma cruzi through ultrastructural analysis by electron microscopy. Many concentrations were used to measure the antiparasitic propriety promoted by imidazolidine derivatives, and our study indicates that parasites treated with 13 μg mL(-1) of the imidazolidine derivates for 24 h revealed severe damage to the parasite's mitochondrial complex. Beyond that, also observed in treated parasites were the following: myelin bodies, enlargement of cytoplasm vacuole, fragmentation of endoplasmic reticulum, and some treated samples clearly showed signs of necrosis. To confirm the ultrastructural results, some assays were performed for knowledge cellular death induction promoted by imidazolidine derivates against immune spleen cells. The induction of the necrotic process through derivatives LPSF/NN-52 and LPSF/NN-100 showed similar results in relation to nifurtimox and benznidazole. In the last assays, it was demonstrated that NN-100 was efficient against epimastigotes and trypomastigotes forms and these results reinforce the mechanisms of action of both new imidazolidine derivatives against T. cruzi.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22941528     DOI: 10.1007/s00436-012-3091-7

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  13 in total

1.  Effects of squalene synthase inhibitors on the growth and ultrastructure of Trypanosoma cruzi.

Authors:  Marina V Braga; Julio A Urbina; Wanderley de Souza
Journal:  Int J Antimicrob Agents       Date:  2004-07       Impact factor: 5.283

2.  Biological and immunological activity of new imidazolidines against adult worms of Schistosoma mansoni.

Authors:  Juliana Kelle de Andrade Lemoine Neves; Sandra Paula Sarinho Botelho; Cristiane Moutinho Lagos de Melo; Valéria Rêgo Alves Pereira; Maria do Carmo Alves de Lima; Ivan da Rocha Pitta; Mônica Camelo Pessoa de Azevedo Albuquerque; Suely Lins Galdino
Journal:  Parasitol Res       Date:  2010-05-04       Impact factor: 2.289

Review 3.  Cell death modalities: classification and pathophysiological implications.

Authors:  L Galluzzi; M C Maiuri; I Vitale; H Zischka; M Castedo; L Zitvogel; G Kroemer
Journal:  Cell Death Differ       Date:  2007-04-13       Impact factor: 15.828

Review 4.  Electron microscopy of trypanosomes--a historical view.

Authors:  Wanderley de Souza
Journal:  Mem Inst Oswaldo Cruz       Date:  2008-06       Impact factor: 2.743

5.  Structural organization of Trypanosoma cruzi.

Authors:  Wanderley de Souza
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-07       Impact factor: 2.743

6.  Effect of oregano (Origanum vulgare L.) and thyme (Thymus vulgaris L.) essential oils on Trypanosoma cruzi (Protozoa: Kinetoplastida) growth and ultrastructure.

Authors:  Giani F Santoro; Maria das Graças Cardoso; Luiz Gustavo L Guimarães; Ana Paula S P Salgado; Rubem F S Menna-Barreto; Maurilio J Soares
Journal:  Parasitol Res       Date:  2006-10-06       Impact factor: 2.289

Review 7.  The extraordinary mitochondrion and unusual citric acid cycle in Trypanosoma brucei.

Authors:  J J van Hellemond; F R Opperdoes; A G M Tielens
Journal:  Biochem Soc Trans       Date:  2005-11       Impact factor: 5.407

8.  Trypanosoma cruzi: altered parasites after in vitro treatment with gangliosides, a therapeutic agent in experimental Chagas' disease.

Authors:  S Cossy Isasi; M Rodríguez; B M I Pereira; C Díaz-Luján; R E Fretes; D I Haüen
Journal:  Exp Parasitol       Date:  2009-04-05       Impact factor: 2.011

9.  Imidazolidines as new anti-Trypanosoma cruzi agents: biological evaluation and structure-activity relationships.

Authors:  M Cristina Caterina; Isabel A Perillo; Lucía Boiani; Horacio Pezaroglo; Hugo Cerecetto; Mercedes González; Alejandra Salerno
Journal:  Bioorg Med Chem       Date:  2007-12-04       Impact factor: 3.641

10.  Selective in vitro effects of the farnesyl pyrophosphate synthase inhibitor risedronate on Trypanosoma cruzi.

Authors:  Luciana R Garzoni; Aura Caldera; Maria de Nazareth L Meirelles; Solange L de Castro; Roberto Docampo; Gary A Meints; Eric Oldfield; Julio A Urbina
Journal:  Int J Antimicrob Agents       Date:  2004-03       Impact factor: 5.283

View more
  3 in total

1.  Further insights into biological evaluation of new anti-Trypanosoma cruzi 5-nitroindazoles.

Authors:  Cristina Fonseca-Berzal; José Antonio Escario; Vicente J Arán; Alicia Gómez-Barrio
Journal:  Parasitol Res       Date:  2014-01-17       Impact factor: 2.289

2.  Mitochondrial Dysfunction Induced by N-Butyl-1-(4-Dimethylamino)Phenyl-1,2,3,4-Tetrahydro-β-Carboline-3-Carboxamide Is Required for Cell Death of Trypanosoma cruzi.

Authors:  Hélito Volpato; Vânia Cristina Desoti; Rodrigo Hinojosa Valdez; Tânia Ueda-Nakamura; Sueli de Oliveira Silva; Maria Helena Sarragiotto; Celso Vataru Nakamura
Journal:  PLoS One       Date:  2015-06-18       Impact factor: 3.240

3.  P-glycoprotein efflux pump plays an important role in Trypanosoma cruzi drug resistance.

Authors:  Mônica Caroline Oliveira Campos; Denise Barçante Castro-Pinto; Grazielle Alves Ribeiro; Márcia Moreira Berredo-Pinho; Leonardo Henrique Ferreira Gomes; Myrtes Santos da Silva Bellieny; Carla Marins Goulart; Aurea Echevarria; Leonor Laura Leon
Journal:  Parasitol Res       Date:  2013-04-10       Impact factor: 2.289

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.